Allergan strengthens Finance Leadership Team with two appointments
pharmafile | December 12, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allergan, MIT, Regeneron, appointment, pharma
The Dublin-headquartered multinational Allergan has appointed two experienced pharma investors to its Finance Leadership Team.
The biopharmaceutical firm yesterday announced that Daphne Karydas and Dr Manisha Narasimhan will join the company effective 10th December 2018.
Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, a position in which she will work with the Executive Leadership Team to develop Allergan’s long term financial strategy.
MIT grad Karydas most recently served as Allergan’s Senior Vice President, Global Investor Relations and Strategy, during which period she was based in New Jersey. Prior to joining the company, Karydas acted as an Executive Director and leading biopharmaceutical sector analyst at J.P. Morgan.
Brent Saunders, Chairman and Chief Executive Officer of Allergan commeted: “We always look to position ourselves to deliver the highest value to patients, customers and shareholders. A strong financial and strategic planning capability is essential to Allergan’s growth, and Daphne’s leadership in this area will help take us to the next level.”
Dr Narasimhan joins Allergan from US firm Regeneron where she led the Investor Relations function. Dr Narasimhan holds a B.Sc. from University of Madras in India and a PhD in Microbiology from New York University.
“With Manisha’s impressive mix of financial and biopharma industry experience, we will continue to build on the solid foundation Daphne set in Investor Relations,” Saunders added.
Both Karydas and Dr Narasimhan will report to Matt Walsh, Executive Vice President and Chief Financial Officer.
“The changes we are announcing today will enable us to further deepen our focus on the corporate strategic and financial planning functions to realize Allergan’s long-term growth potential, while continuing to develop and steward the strong relationships we have established across the financial community,” Walsh said.
Related Content
Regeneron and Mammoth Biosciences announce CRISPR collaboration
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its …
